Terms: = Lymphoma AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Treatment
517 results:
1. BIA-ALCL and BIA-SCC: Updates on Clinical Features and Genetic Mutations for Latest Recommendations.
D'Orsi G; Giacalone M; Calicchia A; Gagliano E; Vannucchi L; Vanni G; Buonomo OC; Cervelli V; Longo B
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38792976
[TBL] [Abstract] [Full Text] [Related]
2. Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells.
Camoglio C; Balla J; Fadda P; Dedoni S
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611871
[TBL] [Abstract] [Full Text] [Related]
3. HBI-8000 improves heart failure with preserved ejection fraction via the TGF-β1/MAPK signalling pathway.
Tian J; Li W; Zeng L; Li Y; Du J; Li Y; Li B; Su G
J Cell Mol Med; 2024 Apr; 28(7):e18238. PubMed ID: 38509729
[TBL] [Abstract] [Full Text] [Related]
4. Antibody targeting of surface P-selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition.
Pereira JL; Ferreira F; Dos Santos NR
Hematol Oncol; 2024 Mar; 42(2):e3257. PubMed ID: 38415859
[TBL] [Abstract] [Full Text] [Related]
5. Anticancer Effects of
Han EJ; Choi EY; Jeon SJ; Moon JM; Lee SW; Lee JH; Jung GH; Han SH; Jung SH; Yang MS; Jung JY
J Med Food; 2024 Apr; 27(4):330-338. PubMed ID: 38387002
[TBL] [Abstract] [Full Text] [Related]
6. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Konopleva MY; Dail M; Daver NG; Garcia JS; Jonas BA; Yee KWL; Kelly KR; Vey N; Assouline S; Roboz GJ; Paolini S; Pollyea DA; Tafuri A; Brandwein JM; Pigneux A; Powell BL; Fenaux P; Olin RL; Visani G; Martinelli G; Onishi M; Wang J; Huang W; Dunshee DR; Hamidi H; Ott MG; Hong WJ; Andreeff M
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):364-374. PubMed ID: 38378362
[TBL] [Abstract] [Full Text] [Related]
7. Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides.
Bordeaux ZA; Reddy SV; Choi J; Braun G; McKeel J; Lu W; Yossef SM; Ma EZ; West CE; Kwatra SG; Kwatra MM
Sci Rep; 2024 Jan; 14(1):1955. PubMed ID: 38263212
[TBL] [Abstract] [Full Text] [Related]
8. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
9. Network and Computational Drug Repurposing Analysis for c-Myc Inhibition in Burkitt lymphoma.
Lee Y; Nam S
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):712-722. PubMed ID: 38035700
[TBL] [Abstract] [Full Text] [Related]
10. Elevated expression of CXCL3 in colon cancer promotes malignant behaviors of tumor cells in an erk-dependent manner.
Cheng Y; Yang X; Liang L; Xin H; Dong X; Li W; Li J; Guo X; Li Y; He J; Zhang C; Wang W
BMC Cancer; 2023 Nov; 23(1):1162. PubMed ID: 38031087
[TBL] [Abstract] [Full Text] [Related]
11. Bio-clickable, small extracellular vesicles-COCKTAIL therapy for ischemic stroke.
Haroon K; Ruan H; Zheng H; Wu S; Liu Z; Shi X; Tang Y; Yang GY; Zhang Z
J Control Release; 2023 Nov; 363():585-596. PubMed ID: 37793483
[TBL] [Abstract] [Full Text] [Related]
12. KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract] [Full Text] [Related]
13. RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells.
Liao WL; Lin H; Li YH; Yang TY; Chen MC
Am J Physiol Cell Physiol; 2023 Nov; 325(5):C1313-C1325. PubMed ID: 37746694
[TBL] [Abstract] [Full Text] [Related]
14. Assessing the Antiproliferative Potential of a Novel Combretastatin A4 Derivative
Nazmy MH; Abu-Baih DH; Elrehany MA; Mustafa M; Aly OM; El-Sheikh AAK; Fathy M
Front Biosci (Landmark Ed); 2023 Aug; 28(8):185. PubMed ID: 37664933
[TBL] [Abstract] [Full Text] [Related]
15. BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes.
Yap J; Yuan J; Ng WH; Chen GB; Sim YRM; Goh KC; Teo J; Lim TYH; Goay SM; Teo JHJ; Lao Z; Lam P; Sabapathy K; Hu J
Mol Cancer; 2023 Aug; 22(1):125. PubMed ID: 37543582
[TBL] [Abstract] [Full Text] [Related]
16. Platycodin D induces apoptotic cell death through PI3K/AKT and MAPK/erk pathways and synergizes with venetoclax in acute myeloid leukemia.
Jiang X; Lin Y; Zhao M; Li Y; Ye P; Pei R; Lu Y; Jiang L
Eur J Pharmacol; 2023 Oct; 956():175957. PubMed ID: 37541375
[TBL] [Abstract] [Full Text] [Related]
17. 2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway.
Mou J; Xie L; Xu Y; Zhou T; Liu Y; Huang Q; Tang K; Tian Z; Xing H; Qiu S; Rao Q; Wang M; Wang J
Cytotherapy; 2023 Oct; 25(10):1080-1090. PubMed ID: 37516949
[TBL] [Abstract] [Full Text] [Related]
18. Molecularly Stratified treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6).
Witte HM; Riedl J; Künstner A; Fähnrich A; Ketzer J; Fliedner SMJ; Reimer N; Bernard V; von Bubnoff N; Merz H; Busch H; Feller A; Gebauer N
Target Oncol; 2023 Sep; 18(5):749-765. PubMed ID: 37488307
[TBL] [Abstract] [Full Text] [Related]
19. Targeting nucleolin improves sensitivity to chemotherapy in acute lymphoblastic leukemia.
Chen Y; Wu Z; Wang L; Lin M; Jiang P; Wen J; Li J; Hong Y; Zheng X; Yang X; Zheng J; Gale RP; Yang T; Hu J
Cell Oncol (Dordr); 2023 Dec; 46(6):1709-1724. PubMed ID: 37486460
[TBL] [Abstract] [Full Text] [Related]
20.
Choi EY; Jung GH; Woo JS; Lee JH; Han SH; Jung SH; Kim SM; Kim EH; Ro JY; Kim KJ; Jung JY
Anticancer Res; 2023 Jul; 43(7):3047-3056. PubMed ID: 37351981
[TBL] [Abstract] [Full Text] [Related]
[Next]
